These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 32306007)

  • 1. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
    Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
    Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
    Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study.
    Li C; Bian X; Liu Z; Wang X; Song X; Zhao W; Liu Y; Yu Z
    Cancer Med; 2021 Dec; 10(23):8352-8364. PubMed ID: 34672424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Ma F; Li Q; Chen S; Zhu W; Fan Y; Wang J; Luo Y; Xing P; Lan B; Li M; Yi Z; Cai R; Yuan P; Zhang P; Li Q; Xu B
    J Clin Oncol; 2017 Sep; 35(27):3105-3112. PubMed ID: 28498781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.
    Li Q; Guan X; Chen S; Yi Z; Lan B; Xing P; Fan Y; Wang J; Luo Y; Yuan P; Cai R; Zhang P; Li Q; Zhong D; Zhang Y; Zou J; Zhu X; Ma F; Xu B
    Clin Cancer Res; 2019 Sep; 25(17):5212-5220. PubMed ID: 31138588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
    Ma F; Ouyang Q; Li W; Jiang Z; Tong Z; Liu Y; Li H; Yu S; Feng J; Wang S; Hu X; Zou J; Zhu X; Xu B
    J Clin Oncol; 2019 Oct; 37(29):2610-2619. PubMed ID: 31430226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
    Xu B; Yan M; Ma F; Hu X; Feng J; Ouyang Q; Tong Z; Li H; Zhang Q; Sun T; Wang X; Yin Y; Cheng Y; Li W; Gu Y; Chen Q; Liu J; Cheng J; Geng C; Qin S; Wang S; Lu J; Shen K; Liu Q; Wang X; Wang H; Luo T; Yang J; Wu Y; Yu Z; Zhu X; Chen C; Zou J;
    Lancet Oncol; 2021 Mar; 22(3):351-360. PubMed ID: 33581774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
    Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
    Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study.
    Yin S; Chi Y; Du Y; Wang J; Shan C; Yi W; Shang M; Man X; Tan Q; Li H
    Cancer Med; 2023 Feb; 12(3):2333-2344. PubMed ID: 35894763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Outcome Analysis of Pyrotinib in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis: A Real-World Study.
    Liang X; Gui X; Yan Y; Di L; Liu X; Li H; Song G
    Oncologist; 2024 Feb; 29(2):e198-e205. PubMed ID: 37589217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial.
    Man X; Huang J; Sun S; Zhou D; Zhang B; Fang S; Zheng F; Li C; Wang X; Huang W; Wang L; He Q; Fu H; Zhang Y; Liu C; Dong L; Zhao X; Xu L; Sun X; Fan B; Song L; Zhou Z; Yu J; Li H
    Clin Transl Med; 2024 May; 14(5):e1687. PubMed ID: 38738791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.
    Wang C; Lin Y; Zhou Y; Mao F; Zhu H; Guan J; Zhang X; Shen S; Huang X; Chen C; Yao R; Zhao J; Sun Q
    BMC Cancer; 2020 Jul; 20(1):653. PubMed ID: 32660609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of first-line dual oral pyrotinib plus capetabine therapy in HER2-positive metastatic breast cancer: A real-world retrospective study.
    Dai S; Zhang Y; Tan X; Luo F; Yan X
    Cancer Med; 2024 Jun; 13(11):e7256. PubMed ID: 38808952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer.
    Sun Y; Chen B; Li J; Peng L; Li S; Yu X; Li L
    Cancer Manag Res; 2021; 13():7165-7174. PubMed ID: 34548820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of pyrotinib-based therapy in lapatinib-resistant metastatic HER2-positive breast cancer.
    Yang C; Shangguan C; Lou G; Qu Q
    Ann Palliat Med; 2022 Jan; 11(1):332-338. PubMed ID: 35144424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience.
    Wu F; Chen M; Wang L; Li N; Wu X; Chen X; Hong Y; Li C; Lin L; Chen K; Huang W; Liu J
    Curr Cancer Drug Targets; 2024; 24(5):490-500. PubMed ID: 37916639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study.
    Li F; Xu F; Li J; Wang T; Bian L; Zhang S; Jiang Z
    Ann Transl Med; 2021 Jan; 9(2):103. PubMed ID: 33569405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-Arm, Prospective Study.
    Jiang K; Hong R; Xia W; Lu Q; Li L; Huang J; Shi Y; Yuan Z; Zheng Q; An X; Xue C; Huang J; Bi X; Chen M; Zhang J; Xu F; Wang S
    Cancer Res Treat; 2024 Apr; 56(2):513-521. PubMed ID: 37846468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Pyrotinib With/Without Trastuzumab in Treatment-Refractory, HER2-Positive Metastatic Colorectal Cancer: Result From a Prospective Observational Study.
    Zhou H; Lv M; Li W; Wang Y; Wu J; Liu Q; Liu T; Cui Y; Li Q
    Clin Colorectal Cancer; 2024 Mar; 23(1):58-66. PubMed ID: 38177002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data.
    Anwar M; Chen Q; Ouyang D; Wang S; Xie N; Ouyang Q; Fan P; Qian L; Chen G; Zhou E; Guo L; Gu X; Ding B; Yang X; Liu L; Deng C; Xiao Z; Li J; Wang Y; Zeng S; Hu J; Zhou W; Qiu B; Wang Z; Weng J; Liu M; Li Y; Tang T; Wang J; Zhang H; Dai B; Tang W; Wu T; Xiao M; Li X; Liu H; Li L; Yi W
    Clin Cancer Res; 2021 Aug; 27(16):4634-4641. PubMed ID: 34112711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.